CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.

Shi, Yunfei

CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients. [electronic resource] - International journal of hematology Sep 2018 - 254-266 p. digital

Publication Type: Journal Article

1865-3774

10.1007/s12185-018-2466-7 doi


Adult
Aged
Aged, 80 and over
Asian People
B7-H1 Antigen--genetics
CD3 Complex
CD8-Positive T-Lymphocytes--pathology
Female
Forecasting
Gene Expression
Humans
Immunohistochemistry
Lymphoma, Large B-Cell, Diffuse--drug therapy
Male
Middle Aged
Prognosis
Rituximab--therapeutic use
Survival
T-Lymphocytes--pathology
Tumor Microenvironment--genetics
Young Adult